CM
EW icon

Capula Management’s Edwards Lifesciences EW Stock Holding History

Capula Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,400
Closed -$192K – 859
2026
Q1 		$192K Buy
+2,400
New +$198K ﹤0.01% 756
2021
Q1 		– Sell
-20,500
Closed -$1.87M – 513
2020
Q4 		$1.87M Buy
+20,500
New +$1.7M 0.09% 177

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Capula Management's EW Position: Q2 2026 in Review

Capula Management sold out of Edwards Lifesciences (EW) in Q2 2026, closing a stake of 460 shares — an estimated $36.8K sold.

Capula Management first reported a position in EW in Q2 2021 and held it in 5 quarters. The position peaked at $964K in Q4 2022. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Capula Management reported no remaining Edwards Lifesciences position as of Q2 2026 after selling out during the quarter.
  • Capula Management sold 460 Edwards Lifesciences shares in Q2 2026, an estimated $36.8K.
  • Capula Management first reported a position in Edwards Lifesciences in Q2 2021 and held it in 5 quarters.
  • Capula Management's Edwards Lifesciences position peaked at $964K in Q4 2022.
  • 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Capula Management's 13F filing for Q2 2026, filed 14 Aug 2026.